Jornay PM (Methylphenidate HCl) Patent Expiration, LOE Window & CMS Spending
Jornay PM (Methylphenidate HCl) by Ironshore A Wholly Owned Sub Of Collegium: FDA Orange Book LOE 2032-03-23, 7 AB generics, $108.9M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ironshore A Wholly Owned Sub Of Collegium |
| FDA Application & Pathway | N209311 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2032-03-23 |
| Orange Book Patents (*PED Extensions) | 16 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 7 |
| 2024 CMS Total Public Spend | $108.9M |
| 2024 Medicare Part D Spend | $1.4M |
| 2024 Medicaid Spend | $107.5M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |